Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic ...

However, the tissue sections cultured on trypticase soy agar ultimately grew Nocardia otitidiscaviarum with intermediate sensitivity to minocycline. Antibiotic therapy was changed to ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Merck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer ...

Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell ...

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...